Tirzepatide

Typical Range

Both Mounjaro and Zepbound share the same pen strengths and titration framework. Starting dose is 2.5 mg weekly for 4 weeks (non-therapeutic initiation), then 5 mg weekly for 4 weeks, with further escalations at 4-week intervals to 7.5 mg, 10 mg, 12.5 mg, and a maintenance ceiling of 15 mg weekly. For type 2 diabetes (Mounjaro), glycemic target achievement often permits stopping titration at 5, 10, or 15 mg. For chronic weight management (Zepbound), the pivotal SURMOUNT trials used 5 mg, 10 mg, and 15 mg maintenance arms; 10 mg and 15 mg produced the largest weight reductions.

Frequency

Once weekly by subcutaneous injection, on the same day each week, with or without regard to meals. Injection timing can be shifted by up to 4 days if necessary to maintain the weekly cadence.

Timing Considerations

Cycle Length

Tirzepatide is intended for indefinite chronic use in both approved indications. The SURMOUNT-4 withdrawal trial demonstrated the same general pattern seen with semaglutide: participants who switched from active drug to placebo after 36 weeks of titration regained roughly 14 percentage points of weight over the following 52 weeks, while those who continued tirzepatide lost an additional 5.5%. The clinical inference is that the underlying condition (obesity) is chronic and pharmacological effect does not persist after discontinuation.

Protocol Notes

Tirzepatide is supplied as a pre-filled single-dose pen injector; no reconstitution, vial-drawing, or needle handling is required. Injection sites are abdomen, thigh, or upper arm, with rotation across sites recommended to minimize injection-site reactions. The 4-week-per-step titration is driven by GI tolerability rather than pharmacokinetics — nausea, vomiting, and diarrhea tend to concentrate in the first week after each dose increase and typically attenuate thereafter. Compared to semaglutide, patient-reported GI side effects are broadly similar in incidence though the distribution across specific symptoms differs slightly. A multi-dose autoinjector pen format has been introduced in some markets, alongside the original single-dose pens.

Onset

Appetite suppression and early satiety are typically reported within the first week of initiation, including at the sub-therapeutic 2.5 mg starting dose. Measurable weight loss is usually evident by week 4–8, and HbA1c trajectories in diabetic patients begin to diverge from placebo within the first month. Full pharmacological effect requires completing titration, which takes a minimum of 20 weeks to reach 15 mg; most trial-reported weight loss accrues during months 4–14 on maintenance dosing.

Peak Effect

In SURMOUNT-1 (72 weeks, n=2,539), mean weight loss at 15 mg was 20.9%, with the curve still sloping downward at trial end. SURMOUNT-4 extended follow-up to 88 weeks and showed continued weight loss during additional maintenance. SURPASS-2 and SURPASS-4 established HbA1c reductions of 2.0–2.6 percentage points at maintenance doses, reached by month 4–6 and sustained. The consensus clinical observation is that weight-loss curves plateau somewhere between month 18 and month 24 for most responders, though individual trajectories vary.

After Discontinuation

SURMOUNT-4 provided the most rigorous discontinuation data: after 36 weeks of open-label titration, participants randomized to placebo regained ~14% of body weight over the subsequent 52 weeks, while the tirzepatide-continuation arm continued to lose. The pharmacokinetic clearance takes approximately 5 weeks given the ~5-day half-life, but the metabolic and appetite-signal effects reverse over a longer window. The pattern mirrors semaglutide: roughly two-thirds of lost weight is regained within a year of stopping if no other intervention replaces the pharmacological effect.

Bloodwork & Labs

• •HbA1c — primary glycemic endpoint, expect a 2.0–2.5 point drop at 15 mg by 40 weeks
• •Fasting glucose and fasting insulin (HOMA-IR)
• •Lipid panel (total, LDL, HDL, triglycerides) — triglycerides often improve before LDL
• •ALT and AST — hepatic fat drops alongside weight; trend toward normalization is expected
• •Lipase and amylase at baseline — anchor values for any later pancreatitis workup

Functional & Performance Tests

• •Body weight (same scale, weekly)
• •Waist circumference
• •Home blood pressure cuff
• •Resting heart rate (wearable) — a 2–5 bpm rise is typical
• •DEXA scan — the lean-mass question matters more here than with most drugs, because the absolute weight drop is larger

When to Test

Baseline, 12 weeks, 24 weeks; weight and waist weekly at home.

Interpretation & Notes

SURMOUNT and SURPASS data set the target: ~20% body weight loss and 2.0–2.5 point HbA1c drop at 15 mg. Tirzepatide's response is typically larger and earlier than semaglutide — by week 12, most responders are already past the 5% weight-loss mark. Same pancreatitis, gallbladder, and muscle-loss cautions as semaglutide apply, but the larger absolute weight loss makes DEXA and resistance training especially worth the cost here; lean-mass loss typically averages 25–40% of total, and you do not get that muscle back easily. If you're on tirzepatide for metabolic reasons and your HbA1c doesn't drop at least 1.0 point by 24 weeks at a therapeutic dose, investigate adherence and source quality before assuming non-response.

United States

Tirzepatide is FDA-approved as Mounjaro (May 2022) for adults with type 2 diabetes and as Zepbound (November 2023) for adults with obesity or overweight with weight-related comorbidities. Zepbound received an additional FDA indication in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity (SURMOUNT-OSA). There are no FDA-approved generics; Eli Lilly's patent protection runs into the 2030s. Compounded tirzepatide exploded during the 2023–2024 branded shortages but the FDA declared the shortage resolved in October 2024, and subsequent litigation and FDA enforcement actions have substantially narrowed the legal pathway for 503A compounding of tirzepatide. 503B outsourcing facilities face tighter restrictions. Some state-level clinical compounding continues under personalized-prescription carve-outs, but this space is legally unsettled as of early 2026.

International

Tirzepatide is authorized by the EMA (Mounjaro since 2022, separately for obesity), the UK MHRA, Health Canada, Australia's TGA, and numerous other regulators for parallel indications. Availability and reimbursement vary: NHS access for the obesity indication is restricted by NICE criteria; several European systems cover diabetes indication more broadly than obesity. Grey-market sourcing is widespread but legally precarious.

Sports & Competition

Tirzepatide is not currently listed by name on the WADA Prohibited List, but WADA has signaled rising scrutiny of GLP-1/GIP agonists in weight-category and endurance sports where rapid body mass reduction or altered energy handling could affect performance classifications. Athletes subject to WADA, USADA, UKAD, or equivalent bodies should verify status and consider TUE requirements before use.